# A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer

> **NCT04677504** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 162 (actual)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab
- **OTHER:** Placebo
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT04677504
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-23
- **Primary completion:** 2022-05-16
- **Final completion:** 2023-08-25
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04677504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04677504, "A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04677504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*